Certificates

We are aware of an issue with certificate availability and are working diligently with the vendor to resolve. The vendor has indicated that, while users are unable to directly access their certificates, results are still being stored. Certificates will be available once the issue is resolved. Thank you for your patience.

(119h) Nanotechnology-Based Targeted Therapies for Perinatal Brain Injury

Authors: 
Kannan, R., Johns Hopkins University School of Medicine
Mishra, M., Johns Hopkins School of Medicine
Balakrishnan, B., Johns Hopkins School of Medicine
Kannan, S., Johns Hopkins University School of Medicine



Neuroinflammation, caused by activated microglia and astrocytes, plays a key role in the pathogenesis of cerebral palsy (CP), and other debilitating neurodegenerative disorders. Engineering and reprogramming the microglial response, to achieve targeted attenuation of neuroinflammation, can be a potent therapeutic strategy. However, drug delivery to the central nervous system is strongly restricted for most drugs by the blood-brain-barrier, making treatment of diffuse neuroinflammation a challenge. We take advantage of the unique, intrinsic, pathology-dependent, biodistribution patterns of dendrimers (with no targeting moieties) in diseases models of neurodegeneration. For example, dendrimers are transported to the periventricular region of the brain of newborn rabbit kits with cerebral palsy (CP), whereas little brain uptake is seen in healthy animals. Interestingly, they further localize selectively in activated microglia and astrocytes in animals with CP. Such selective localization in activated microglia is also seen in retinal degeneration models, upon intravitreal administration.1 Building on these findings, we have designed and synthesized dendrimer-drug nanodevices, taking advantage of their rich surface functionality using appropriate linking chemistry. They can deliver and release the drug in the targeted tissue in a tailored and sustained manner. We show that a single intravenous dose of dendrimer-drug conjugate, administered after birth to rabbit kits with CP, results in significant improvement in motor function along with decrease in neuroinflammation and oxidative/neuronal injury, followed by improved myelination, by 5 days of age.1 These studies suggest that attenuation of ongoing neuroinflammation, achieving by appropriate engineering of the glial response, can have significant positive consequences in these and other debilitating neurodegenerative diseases. Application of this approach to designing dendrimer-based targeted therapeutic platforms is being explored in a variety of systemic inflammation and neuroinflammation-associated disorders, especially in the perinatal period.  

References:

 

1. S Kannan, H Dai, RS Navath, B Balakrishnan, A Jyoti, J Janisse, R Romero, RM Kannan (2012). 'Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model'. Science Translational Medicine, 4(130), p. 130ra46. Highlighted in Nature, Science, Nature Review Drug Discovery.

2. R Iezzi, B Raja Guru, I Glybina, M Mishra, A Kennedy, RM Kannan (2012). 'Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration'. Biomaterials, 33(3), 979-988.